Tissue distribution and pharmacodynamics of rivastigmine after intranasal and intravenous administration in rats

Current Alzheimer Research

Volumn 9, Issue 3, 2012, Pages 315-325

  Yang, Zhen zhen ^a   Zhang, Yan qing ^b   Wu, Kai ^a   Wang, Zhan zhang ^a   Qi, Xian rong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b TIANJIN UNIVERSITY OF COMMERCE   (China)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Brain delivery; Butyrylcholinesterase; Intranasal administration; Rivastigmine

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; RIVASTIGMINE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CEREBELLUM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; HIPPOCAMPUS; MALE; NONHUMAN; OLFACTORY EPITHELIUM; PHARMACODYNAMICS; PLASMA; PRIORITY JOURNAL; RAT; SYSTEMIC CIRCULATION; TISSUE DISTRIBUTION;

ACETYLCHOLINESTERASE; ADMINISTRATION, INTRANASAL; ANIMALS; BLOOD-BRAIN BARRIER; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; DOWN-REGULATION; INJECTIONS, INTRAVENOUS; MALE; PHENYLCARBAMATES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84860308373     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512800107528     Document Type: Article

References (36)

1. Cummings JL, Mendez MF. Alzheimer's disease: cognitive and behavioral pharmacotherapy. Conn Med 61: 543-552 (1997).
2. Mutlu NB, Degim Z. Bioavailability file: rivastigmine tartrate. J Pharm Sci 30: 150-157 (2005).
3. Reena SS, Hyoung-Gon L, Zhu XW, George P, Mark AS, Rudy JC. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother 62: 199-207 (2008).
4. Lawrence AD, Sahakian BJ. Alzheimer disease, attention, and the cholinergic system. Alz Dis Assoc Disord 9 Suppl 2: 43-49 (1995).
5. Jaen JC, Davis RE. Cholinergic therapies for Alzheimer's disease: acetylcholinesterase inhibitors of current clinical interest. Curr Opin Invest Drug 2: 363-77 (1993).
6. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of acetyl-and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 109: 1053-1065 (2002).
7. Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, et al. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 41: 3555-3564 (2002).
8. Spencer CM, Noble S. Rivastigmine, a review of its use in Alzheimer's Disease. Drugs Aging 13: 391-411 (1998).
9. Venkatesh K, Bullock R, Akbas A. Strategies to improve tolerability of rivastigmine: a case series. Curr Med Res Opin 23: 93-95 (2007).
10. Tenovuo O. Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients. Prog Neuro-Psychopharmacol Biol Psychiatry 29: 61-67 (2005).
11. Hussain AA. Intranasal drug delivery. Adv Drug Deliv Rev 29: 39-49 (1998).
12. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 87: 187-198 (2003).
13. Dahlin M, Bergman U, Jansson B, Björk E, Brittebo E. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res 17: 737-742 (2000).
14. Eriksson C, Bergman U, Franzén A, Sjöblom M, Brittebo EB. Transfer of some carboxylic acids in the olfactory system following intranasal administration. J Drug Target 7: 131-142 (1999).
15. 125I-NGF to the brain via the olfactory route. Drug Deliv 4: 87-92 (1997).
16. Hirai S, Yashiki T, Matsuzawa H, Mima, H. Absorption of drugs from the nasal mucosa of rat. Int J Pharm 7: 317-325 (1981).
17. Albert E, Alain C, Andre D. A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry. Biomed Chromatogr 18: 160-166 (2004).
18. Scalil C, Casamenti F, Bellucci A, Costagli C, Schmidt B, Pepeu G. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J Neural Transm 109: 1067-1080 (2002).
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 72: 248-54 (1976).
20. DeLaGarza VW. Pharmacologic treatment of Alzheimer's disease: an update Am. Fam. Physician. 68: 1365-1372 (2003).
21. Winblad B, Cummings J, Andreasen N, Grossbery G, Onofrj M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease: rivastigmine patch versus capsule. Int J Geriatr Psychiatry 22: 456-467 (2007).
22. Alexis KL, Anthony PS, Conor M, Charles AF, Steven CQ, Henery RC. Development of a novel high-concentration galantamine formulation Suitable for intranasal Delivery. J Pharm Sci 94: 1736-1746 (2005).
23. Kaur P, Kim K. Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. Int J Pharm 364: 27-35 (2008).
24. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 11: 1-18 (2000).
25. Mygind N, Dahl R. Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev 29: 3-12 (1998).
26. Shi Z, Zhang Q, Jiang X. Pharmacokinetic behavior in plasma, cerebrospinal fluid and cerebral cortex after intranasal administration of hydrochloride meptazinol. Life Sci 77: 2574-2583 (2005).
27. nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99: 1654-1683 (2010).
28. Williams BR, Nazarians A, Gill MA. A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Ther 25: 1651-1653 (2003).
29. Cutler NR, Polinsky RJ, Sramek JJ, Enz A, Jhee SS, Mancione L, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA713 in Alzheimer's disease. Acta Neurol Scand 97: 244-250 (1998).
30. Jann MW. Rivastigmine, a new generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20: 1-12 (2000).
31. Ronald JP. Clinical Pharmacology of Rivastigmine: A Newgeneration acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 20: 634-647 (1998).
32. Ballard CG. Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition. Eur Neurol. 47: 64-70 (2002).
33. Ibach B, Haen E. Acetylcholinesterase inhibition in Alzheimer's disease. Curr Pharm Design 10: 231-251 (2004).
34. Weinstock M, Razin M, Chorev M, Enz A. Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm Suppl 43: 219-225 (1994).
35. Jackisch R, Forster S, Kammerer M, Rothmaier AK, Ehret A, Zentner J, et al. Inhibitory potency of choline esterase inhibitors on acetylcholine Release and choline esterase activity in fresh specimens of human and rat neocortex. J Alzheimer's Dise 16: 635-647 (2009).
36. Liang YQ, Tang XC. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats. Acta Pharmco Sin 27: 1127-1136 (2006).